Cyclooxygenase Inhibition and Mechanisms of Colorectal Cancer Prevention

Current Cancer Drug Targets

Volumn 3, Issue 6, 2003, Pages 455-463

  Chan, Timothy A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Apoptosis; Arachidonic acid; Cancer; Chemoprevention; Colon; Cyclooxygenase; Nonsteroidal anti inflammatory drug

Indexed keywords

CELECOXIB; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE; ROFECOXIB;

ANTINEOPLASTIC ACTIVITY; CANCER MORTALITY; CANCER PREVENTION; CARCINOGENESIS; COLORECTAL CANCER; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; PREVALENCE; REVIEW;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS;

EID: 0346881625     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009033481723     Document Type: Review

References (112)

1. Tattersal, M. H. N.; Thomas, H. Recent Advances: Oncology. Brit. Med. J. 1999, 318, 445-448.
2. Thun, M.; Nambooridi, M.; Heath Jr, C. Aspirin Use and Reduced Risk of Fatal Colon Cancer. N. Engl. J. Med. 1991, 325, 1593-1596.
3. Giovannucci, E.; Rimm, E. B.; Stampfer, M. J.; Colditz, G. A.; Ascherio, A.; Willett, W. C. Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health Professionals. Ann. Intern. Med. 1994, 121, 241-246.
4. Peleg, I. I.; Lubin, M. F.; Cotsonis, G. A.; Clark, W. S.; Wilcox, C. M. Long-Term Use of Nonsteroidal Anti-Inflammatory Drugs and Other Chemopreventors and Risk of Subsequent Colorectal Neoplasia. Dig. Dis. Sci. 1996, 41, 1319-1326.
5. Peleg, I. I.; Maibach, H. T.; Brown, S. H.; Wilcox, C. M. Aspirin and Nonsteroidal Anti-Inflammatory Drug Use and the Risk of Subsequent Colorectal Cancer. Arch. Intern. Med. 1994, 154, 394-399.
6. Muscat, J. E.; Stellman, S. D.; Wynder, E. L. Nonsteroidal Anti-Inflammatory Drugs and Colorectal Cancer. Cancer 1994, 74, 1847-1854.
7. Kinzler, K. W.; Nilbert, M. C.; Su, L. K.; Vogelstein, B.; Bryan, T. M.; Levy, D. B.; Smith, K. J.; Preisinger, A. C.; Hedge, P.; Mckechnie, D.; Finniear, R.; Markham, A.; Groffen, J.; Boguski, M. S.; Altschul, S. F.; Horii, A.; Ando, H.; Miyoshi, Y.; Miki, Y.; Nishisho, I.; Nakamura, Y. Identification of FAP Locus Genes from Chromosome 5q21. Science 1991, 253, 661-665.
8. Giardiello, F. M.; Hamilton, S. R.; Krush, A. J.; Piantadosi, S.; Hylind, L. M.; Celano, P.; Booker, S. V.; Robinson, C. R.; Offerhaus, G. J. Treatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis. N. Engl. J. Med. 1993, 328, 1313-1316.
9. Labayle, D.; Fischer, D.; Vielh, P.; Drouhin, F.; Pariente, A.; Bories, C.; Duhamel, O.; Trousset, M.; Attali, P. Sulindac Causes Regression of Rectal Polyps in Familial Adenomatous Polyposis. Gastroenterology 1991, 101, 635-639.
10. Rigau, J.; Pique, J. M.; Rubio, E.; Planas, R.; Tarrech, J. M.; Bordas, J. M. Effects of Long-Term Sulindac Therapy on Colonic Polyposis. Ann. Intern. Med. 1991, 115, 952-954.
11. Spagnesi, M. T.; Tonelli, F.; Dolara, P. Rectal Proliferation and Polyp Occurence in Patients with Familial Adenomatous Polyposis after Sulindac Treatment. Gastroenterology 1994, 106, 362-366.
12. Waddell, W. R.; Ganser, G. F.; Cerise, E. J.; Loughry, R. W. Sulindac for Polyposis of the Colon. Am. J. Surg. 1989, 157, 175-179.
13. Vane, J. R. Introduction: Mechanism of Action of Nsaids. Br. J. Rheumatol. 1996, 35, 1-3.
14. Smith, W. L. Cyclooxygenases: Structural, Cellular, and Molecular Biology. Annu. Rev. Biochem. 2000, 69, 145-184.
15. Jones, D.; Carlton, D.; Mcintyre, T.; Zimmerman, G.; Prescott, S. Molecular Cloning of Human Prostaglandin Endoperoxide Synthase Type II and Demonstration of Expression N Response to Cytokines. J. Biol. Chem. 1993, 268, 9049-9054.
16. Eberhart, C. E.; Coffey, R. J.; Radhika, A.; Giardiello, F. M.; Ferrenbach, S.; Dubois, R. N. Up-Regulation of Cyclooxygenase 2 Gene Expression in Human Colorectal Adenomas and Adenocarcinomas. Gastroenterology 1994, 107, 1183-1188.
17. Fujita, T.; Matsui, M.; Takaku, K.; Uetake, H.; Ichikawa, W.; Taketo, M. M.; Sugihara, K. Size- and Invasion-Dependent Increase in Cyclooxygenase 2 Levels in Human Colorectal Carcinomas. Cancer Res. 1998, 58, 4823-4826.
18. Rigas, B.; Goldman, I. S.; Levine, L. Altered Eicosanoid Levels in Human Colon Cancer. J. Lab. Clin. Med. 1993, 122, 518-523.
19. Dubois, R. N.; Radhika, A.; Reddy, B. S.; A. J., E. Increased Cyclooxygenase-2 Levels in Carcinogen-Induced Rat Colonic Tumors. Gastroenterology 1996, 111, 1259-1262.
20. Williams, C. S.; Luongo, C.; Radhika, A.; Zhang, T.; Lamps, L. W.; Nanney, L. B.; Beauchamp, R. D.; Dubois, R. N. Elevated Cyclooxygenase-2 Levels in Min Mouse Adenomas. Gastroenterology 1996, 111, 1134-1140.
21. Half, E.; Tang, X. M.; Gwyn, K.; Sahin, A.; Wathen, K.; Sinicrope, F. A. Cyclooxygenase-2 Expression in Human Breast Cancers and Adjacent Ductal Carcinoma in Situ. Cancer Res. 2002, 62, 1676-1681.
22. Salmenkivi, K.; Haglund, C.; Ristimaki, A.; Arola, J.; Heikkila, P. Increased Expression of Cyclooxygenase-2 in Malignant Pheochromocytomas. J. Clin. Endocrinol. Metab. 2001, 86, 5615-5619.
23. An, K. P.; Athar, M.; Tang, X.; Katiyar, S. K.; Russo, J.; Beech, J.; Aszterbaum, M.; Kopelovich, L.; Epstein, E. H. J.; Mukhtar, H.; Bickers, D. R. Cyclooxygenase-2 Expression in Murine and Human Nonmelanoma Skin Cancers: Implications for Therapeutic Approaches. Photochem. Photobiol. 2002, 76, 73-80.
24. Koga, H.; Sakisaka, S.; Ohishi, M.; Kawaguchi, T.; Taniguchi, E.; Sasatomi, K.; Harada, M.; Kusaba, T.; Tanaka, M.; Kimura, R.; Nakashima, Y.; Nakashima, O.; Kojiro, M.; Kurohiji, T.; Sata, M. Expression of Cyclooxygenase-2 in Human Hepatocellular Carcinoma: Relevance to Tumor Dedifferentiation. Hepatology 1999, 29, 688-696.
25. Dannenberg, A. J. Cyclo-Oxygenase 2: A Pharmacological Target for the Prevention of Cancer. Lancet Oncology 2001, 2, 544-551.
26. Kinzler, K. W.; Vogelstein, B. Lessons from Hereditary Colon Cancer. Cell 1996, 87, 159-170.
27. Araki, Y.; Okamura, S.; Hussain, S. P.; Nagashima, M.; He, P.; Shiseki, M.; Miura, K.; Harris, C. C. Regulation of Cyclooxygenase-2 Expression by the Wnt and Ras Pathways. Cancer Res. 2003, 63, 728-734.
28. Fujita, M.; Fukui, H.; Kusaka, T.; Morita, K.; Fujii, S.; Ueda, Y.; Chiba, T.; Sakamoto, C.; Kawamata, H.; Fujimori, T. Relationship between Cyclooxygenase-2 Expression and K-Ras Gene Mutation in Colorectal Adenomas. J. Gastroenterol. Hepatol. 2000, 15, 1277-1281.
29. Gilhooly, E. M.; Rose, D. P. the Association between A Mutated Ras Gene and Cyclooxygenase-2 Expression in Human Breast Cancer Cell Lines. Int. J. Oncol. 1999, 15, 267-270.
30. Forrester, K.; Almoguera, C.; Han, K.; Grizzle, W. E.; Perucho, M. Detection of High Incidence of K-Ras Oncogenes During Human Colon Tumorigenesis. Nature 1987, 327, 298-303.
31. Farr, C. J.; Marshall, C. J.; Easty, D. J.; Wright, N. A.; Powell, S. C. ; Paraskeva, C. A Study of Ras Gene Mutations in Colonic Adenomas from Familial Polyposis Coli Patients. Oncogene 1988, 3, 673-678.
32. Sheng, H.; Shao, J.; Dixon, D. A.; Williams, C. S.; Prescott, S. M.; Dubois, R. N.; Beauchamp, R. D. TGF-β1 Enhances Ha-Ras-Induced Expression of Cyclooxygenase-2 in Intestinal Epithelial Cells via Stabilization of Mrna. J. Biol. Chem. 2000, 275, 6628-6635.
33. Oshima, M.; Dinchuk, J. E.; Kargman, S. L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J. M.; Evans, J. F.; Taketo, M. M. Suppression of Intestinal Polyposis in APC (716) Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2). Cell 1996, 87, 803-809.
34. Liu, C. H.; Chang, S. H.; Narko, K.; Trifan, O. C.; Wu, M. T.; Smith, E. ; Haudenschild, C.; Lane, T. F.; Hla, T. Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice. J. Biol. Chem. 2001, 276, 18563-18569.
35. Neufang, G.; Furstenberger, G.; Heidt, M.; Marks, F.; Muller-Decker, K. Abnormal Differentiation of Epidermis in Transgenic Mice Constitutively Expressing Cyclooxygenase-2 in Skin. Proc. Natl. Acad. Sci. USA 2001, 98, 7629-7634.
36. Muller-Decker, K.; Neufang, G.; Berger, I.; Neumann, M.; Marks, F.; Furstenberger, G. Transgenic Cyclooxygenase-2 Overexpression Sensitizes Mouse Skin for Carcinogenesis. Proc. Natl. Acad. Sci. USA 2002, 99, 12483-12488.
37. Shibata, H.; Toyama, K.; Shioya, H.; Ito, M.; Hirota, M.; Hasegawa, S.; Matsumoto, H.; Takano, H.; Akiyama, T.; Toyoshima, K.; Kanamaru, R.; Kanegae, Y.; Saito, I.; Nakamura, Y.; Shiba, K.; Noda, T. Rapid Colorectal Adenoma Formation Initiated by Conditional Targeting of the Apc Gene. Science 1997, 278, 120-123.
38. Beazer-Barclay, Y.; Levy, D. B.; Moser, A. M.; Dove, W. F.; Hamilton, S. R.; Vogelstein, B.; Kinzler, K. W. Sulindac Suppresses Tumorigenesis in the Min Mouse. Carcinogenesis 1996, 17, 1757-1760.
39. Chiu, C.-H.; Mcentee, M. F.; Whelan, J. Sulindac Causes Rapid Regression of Preexisting Tumors in Min/+ Mice Independent of Prostaglandin Biosynthesis. Cancer Res. 1997, 57, 4267-4273.
40. Mahmoud, N. N.; Boolbol, S. K.; Dannenberg, A. J.; Mestre, J. R.; Bilinski, R. T.; Martucci, C.; Newmark, H. L.; Chadburn, A.; Bertagnolli, M. M The Sulfide Metabolite of Sulindac Prevents Tumors and Restores Enterocyte Apoptosis in A Murine Model of Familial Adenomatous Polyposis. Carcinogenesis 1998, 19, 87-91.
41. Boolbol, S. K.; Dannenberg, A. J.; Chadurn, A.; Martucci, C.; Guo, X.; Ramonetti, J. T.; Abreu-Goris, M.; Newmark, H. L.; Lipkin, M. L.; Decosse, J. J.; Bertagnolli, M. M. Cyclooxygenase-2 Overexpression and Tumor Formation Are Blocked by Sulindac in A Murine Model of Familial Adenomatous Polyposis. Cancer Res. 1996, 56, 2556-2560.
42. Mahmoud, N.; Dannenberg, A.; Mestre, J.; Bilinski, R.; Churchill, M.; Martucci, C.; Newmark, H.; Bertagnolli, M. Aspirin Prevents Tumors in A Murine Model of Familial Adenomatous Polyposis. Surgery 1998, 124, 225-231.
43. Jacoby, R. F.; Marshall, D. J.; Newton, M. A.; Novakovic, K.; Tutsch, K. ; Cole, C. E.; Lubet, R. A.; Kelloff, G. J.; Verma, A.; Moser, A. R.; Dove, W. F. Chemoprevention of Spontaneous Intestinal Adenomas in the APC-Min Mouse by the Nonsteroidal Anti-Inflammatory Drug Piroxicam. Cancer Res. 1996, 56, 710-714.
44. Wechter, W.; Kantoci, D.; Murray, E.; Quiggle, D.; Leipold, D.; Gibson, K.; Mccracken, J. R-Flurbiprofen Chemoprevention and Treatment of Intestinal Adenomas in the APC(Min)/+ Mouse Model: Implications for Prophylaxis and Treatment of Colon Cancer. Cancer Res. 1997, 57, 4316-4324.
45. Chiu, C. H.; Mcentee, M. F.; Whelan, J. Discordant Effect of Aspirin and Indomethacin on Intestinal Tumor Burden in Apc(Min/+)Mice. Prostaglandins Leukot. Essent. Fatty Acids 2000, 62, 269-275.
46. Pollard, M.; Luckert, P. H. Effect of Indomethacin on Intestinal Tumors Induced in Rats by the Acetate Derivative of Dimethylnitrosamine. Science 1981, 214, 558-559.
47. Skinner, S. A.; Penney, A. G.; Pe, O. B. Sulindac Inhibits the Rate of Growth and Appearance of Colon Tumors in the Rat. Arch. Surg. 1991, 126, 1094-1096.
48. Steinbach, G.; Lynch, P.; Phillips, R.; Wallace, M.; Hawk, E.; Gordon, G.; Wakabayashi, N.; Saunders, B.; Shen, Y.; Fujimura, T.; Su, L.; Levin, B. the Effect of Celecoxib, A Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis. N. Engl. J. Med. 2000, 342, 1946-1952.
49. Phillips, R. K.; Wallace, M. H.; Lynch, P. M.; Hawk, E.; Gordon, G. B.; Saunders, B. P.; Wakabayashi, N.; Shen, Y.; Zimmerman, S.; Godio, L.; Rodrigues-Bigas, M.; Su, L. K.; Sherman, J.; Kelloff, G.; Levin, B.; Steinbach, G.; Group, F. S. A Randomised, Double Blind, Placebo-Controlled Study of Celecoxib, A Selective Cyclooxygenase 2 Inhibitor, on Duodenal Polyposis in Familial Adenomatous Polyposis. Gut 2002, 50, 857-860.
50. Oshima, M.; Murai, N.; Kargman, S.; Arguello, M.; Luk, P.; Kwong, E.; Taketo, M.; Evans, J. Chemoprevention of Intestinal Polyposis in the Apcdelta716 Mouse by Rofecoxib, A Specific Cyclooxygenase-2 Inhibitor. Cancer Res. 2001, 61, 1733-1740.
51. Jacoby, R. F.; Seibert, K.; Cole, C. E.; Kelloff, G.; Lubet, R. A. the Cyclooxygenase-2 Inhibitor Celecoxib Is A Potent Preventive and Therapeutic Agent in the Min Mouse Model of Adenomatous Polyposis. Cancer Res. 2000, 60, 5040-5044.
52. Silverstein, F. E.; Faich, G.; Goldstein, J. L.; Simon, L. S.; Pincus, T.; Whelton, A.; Makuch, R.; Eisen, G.; Agrawal, N. M.; Stenson, W. F.; Burr, A. M.; Zhao, W. W.; Kent, J. D.; Lefkowith, J. B.; Verburg, K. M.; Geis, G. S. Gastrointestinal Toxicity with Celecoxib Vs Nonsteroidal Anti-Inflammatory Drugs for Osteoarthritis and Rheumatoid Arthritis: the CLASS Study: A Randomized Controlled Trial. Celecoxib Long-Term Arthritis Safety Study. J. Am. Med. Assoc. 2000, 284, 1247-1255.
53. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal Anti-Inflammatory Drugs As Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues. J. Natl. Cancer Inst. 2002, 94, 252-266.
54. Giardiello, F. M.; Yang, V. W.; Hylind, L. M.; Krush, A. J.; Petersen, G. M.; Trimbath, J. D.; Piantadosi, S.; Garrett, E.; Geiman, D. E.; Hubbard, W.; Offerhaus, G. J.; Hamilton, S. R. Primary Chemoprevention of Familial Adenomatous Polyposis with Sulindac. N. Engl. J. Med 2002, 346, 1054-1059.
55. Cruz-Correa, M.; Hylind, L. M.; Romans, K. E.; Booker, S. V.; Giardiello, F. M. Long-Term Treatment with Sulindac in Familial Adenomatous Polyposis: A Prospective Cohort Study. Gastroenterology 2002, 122, 641-645.
56. Hall, P. A.; Coates, P. J.; Ansari, B.; Hopwood, D. Regulation of Cell Number in the Mammalian Gastrointestinal Tract: the Importance of Apoptosis. Journal of Cell Science 1994, 107, 3569-3577.
57. Bedi, A.; Pasricha, P. J.; Akhtar, A. J.; Barber, J. P.; Bedi, G. C.; Giardiello, F. M.; Zehnbauer, B. A.; Hamilton, S. R.; Jones, R. J. Inhibition of Apoptosis During Development of Colorectal Cancer. Cancer Res. 1995, 55, 1811-1816.
58. Pasricha, P. J.; Bedi, A.; K. O. C.; Rashid, A.; Akhtar, A. J.; Zahurak, M. L.; Piantadosi, S.; Hamilton, S. R.; Giardiello, F. M. the Effects of Sulindac on Colorectal Proliferation and Apoptosis in Familial Adenomatous Polyposis. Gastroenterology 1995, 109, 994-998.
59. Arico, S.; Pattingre, S.; Bauvy, C.; Gane, P.; Barbat, A.; Codogno, P.; Ogier-Denis, E. Celecoxib Induces Apoptosis by Inhibiting 3-Phosphoinositide-Dependent Protein Kinase-1 Activity in the Human Colon Cancer HT-29 Cell Line. J. Biol. Chem. 2002, 277, 27613-27621.
60. Shiff, S. J.; Qiao, L.; Tsai, L. L.; Rigas, B. Sulindac Sulfide, An Aspirin-Like Compound, Inhibits Proliferation, Causes Cell Cycle Quiescence, and Induces Apoptosis in HT-29 Colon Adenocarcinoma Cells. J. Clin. Invest. 1995, 96, 491-503.
61. Chan, T. A.; Morin, P. J.; Vogelstein, B.; Kinzler, K. W. Mechanisms Underlying Nonsteroidal Antiinflammatory Drug-Mediated Apoptosis. Proc. Natl. Acad. Sci., U.S.A. 1998, 95, 681-686.
62. Shiff, S. J.; Koutsos, M. I.; Qiao, L.; Rigas, B. Nonsteroidal Antiinflammatory Drugs Inhibit the Proliferation of Colon Adenocarcinoma Cells: Effects on Cell Cycle and Apoptosis. Exp. Cell Res. 1996, 222, 179-188.
63. Qiao, L.; Hanif, R.; Sphicas, E.; Schiff, S. J.; Rigas, B. Effect of Aspirin on Induction of Apoptosis in HT-29 Human Colon Adenocarcinoma Cells. Biochem. Pharmacol. 1998, 55, 53-64.
64. Tsujii, M.; Dubois, R. N. Alterations in Cellular Adhesion and Apoptosis in Epithelial Cells Overexpressing Prostaglandin Endoperoxide Synthase 2. Cell 1995, 83, 493-501.
65. Tang, X.; Sun, Y. J.; Half, E.; Kuo, M. T.; Sinicrope, F. Cyclooxygenase-2 Overexpression Inhibits Death Receptor 5 Expression and Confers Resistance to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis in Human Colon Cancer Cells. Cancer Res. 2002, 62, 4903-4908.
66. Sun, Y.; Tang, X. M.; Half, E.; Kuo, M. T.; Sinicrope, F. A. Cyclooxygenase-2 Overexpression Reduces Apoptotic Susceptibility by Inhibiting the Cytochrome C-Dependent Apoptotic Pathway in Human Colon Cancer Cells. Cancer Res. 2002, 62, 6323-6328.
67. Hansen-Petrik, M. B.; Mcentee, M. F.; Jull, B.; Shi, H.; Zemel, M. B.; Whelan, J. Prostaglandin E(2) Protects Intestinal Tumors from Nonsteroidal Anti-Inflammatory Drug-Induced Regression in Apc(Min/+) Mice. Cancer Res. 2002, 62, 403-408.
68. Qiao, L.; Kozoni, V.; Tsioulias, G. J.; Koutsos, M. I.; Hanif, R.; Shiff, S. J.; Rigas, B. Selected Eicosanoids Increase the Proliferation Rate of Human Colon Carcinoma Cell Lines and Mouse Colonocytes in Vivo. Biochim. Biophys. Acta 1995, 1258, 215-223.
69. Sonoshita, M.; Takaku, K.; Sasaki, N.; Sugimoto, Y.; Ushikubi, F.; Narumiya, S.; Oshima, M.; Taketo, M. M. Acceleration of Intestinal Polyposis through Prostaglandin Receptor EP2 in Apc(Delta 716) Knockout Mice. Nat. Med. 2001, 7, 1048-1051.
70. Zhang, L.; Yu, J.; Park, B.-H.; Kinzler, K. W.; Vogelstein, B. Role of BAX in the Apoptotic Response to Anti-Cancer Agents. Science 2000, 290, 989-992.
71. Sheng, H. M.; Shao, J. Y.; Morrow, J. D.; Beauchamp, R. D.; Dubois, R. N. Modulation of Apoptosis and Bcl-2 Expression by Prostaglandin E-2 in Human Colon Cancer Cells. Cancer Res. 1998, 58, 362-366.
72. Mcginty, A.; Chang, Y. W.; Sorokin, A.; Bokemeyer, D.; Dunn, M. J. Cyclooxygenase-2 Expression Inhibits Trophic Withdrawal Apoptosis in Nerve Growth Factor-Differentiated PC12 Cells. J. Biol. Chem. 2000, 275, 12095-12101.
73. Chang, Y. W.; Jakobi, R.; Mcginty, A.; Foschi, M.; Dunn, M. J.; Sorokin, A. Cyclooxygenase 2 Promotes Cell Survival by Stimulation of Dynein Light Chain Expression and Inhibition of Neuronal Nitric Oxide Synthase Activity. Mol. Cell. Biol. 2000, 20, 8571-8579.
74. Von Knethen, A.; Brune, B. Cyclooxygenase-2: An Essential Regulator of NO-Mediated Apoptosis. FASEB J. 1997, 11, 887-895.
75. Lagares-Garcia, J. A.; Moore, R. A.; Collier, B.; Heggere, M.; Diaz, F.; Qian, F. Nitric Oxide Synthase As A Marker in Colorectal Carcinoma. Am. Surg. 2001, 67, 709-713.
76. Ambs, S.; Merriam, W. G.; Bennett, W. P.; Felley-Bosco, E.; Ogunfusika, M. O.; Oser, S. M.; Klein, S.; Shields, P. G.; Billiar, T. R.; Harris, C. C. Frequent Nitric Oxide Synthase-2 Expression in Human Colon Adenomas: Implication for Tumor Angiogenesis and Colon Cancer Progression. Cancer Res. 1998, 58, 334-341.
77. Jayadev, S.; Linardic, C. M.; Hannun, Y. A. Identification of Arachidonic Acid As A Mediator of Sphingomyelin Hydrolysis in Response to Tumor Necrosis Factor Alpha. J. Biol. Chem. 1994, 269, 5757-5763.
78. Kolesnick, R. N.; Haimovitz-Friedman, A.; Fuks, Z The Sphingomyelin Signal Transduction Pathway Mediates Apoptosis for Tumor Necrosis Factor, Fas, and Ionizing Radiation. Biochem. Cell. Biol. 1994, 72, 471-474.
79. Cao, Y.; Pearman, A. T.; Zimmerman, G. A.; Mcintyre, T. M.; Prescott, S. M. Intracellular Unesterified Arachidonic Acid Signals Apoptosis. Proc. Natl. Acad. Sci. USA 2000, 97, 11280-11285.
80. Zhao, S.; Du, X. Y.; Chai, M. Q.; Chen, J. S.; Zhou, Y. C.; Song, J. G. Secretory Phospholipase A(2) Induces Apoptosis Via A Mechanism Involving Ceramide Generation. Biochim. Biophys. Acta 2002, 1581, 75-88.
81. Scorrano, L.; Penzo, D.; Petronilli, V.; Pagano, F.; Bernardi, P. Arachidonic Acid Causes Cell Death through the Mitochondrial Permeability Transition. Implications for Tumor Necrosis Factor-Alpha Apoptotic Signaling. J. Biol. Chem. 2001, 276, 12035-12040.
82. Kalyankrishna, S.; Parmentier, J. H.; Malik, K. U. Arachidonic Acid-Derived Oxidation Products Initiate Apoptosis in Vascular Smooth Muscle Cells. Prostaglandins Other Lipid Mediat. 2002, 70, 13-29.
83. Tsujii, M.; Kawano, S.; Tsuji, S.; Sawaoka, H.; Hori, M.; Dubois, R. N. Cyclooxygenase Regulates Angiogenesis Induced by Colon Cancer Cells. Cell 1998, 93, 705-716.
84. Li, G.; Yang, T.; Yan, J. Cyclooxygenase-2 Increased the Angiogenic and Metastatic Potential of Tumor Cells. Biochem. Biophys. Res. Commun. 2002, 299, 886-890.
85. Cianchi, F.; Cortesini, C.; Bechi, P.; Fantappie, O.; Messerini, L.; Vannacci, A.; Sardi, I.; Baroni, G.; Boddi, V.; Mazzanti, R.; Masini, E. Up-Regulation of Cyclooxygenase 2 Gene Expression Correlates with Tumor Angiogenesis in Human Colorectal Cancer. Gastroenterology 2001, 121, 1339-1347.
86. Konno, H.; Baba, M.; Shoji, T.; Ohta, M.; Suzuki, S.; Nakamura, S. Cyclooxygenase-2 Expression Correlates with Upar Levels and Is Responsible for Poor Prognosis of Colorectal Cancer. Clin. Exp. Metastasis 2002, 19, 527-534.
87. Jones, M. K.; Wang, H.; Peskar, B. M.; Levin, E.; Itani, R. M.; Sarfeh, I. J.; Tarnawski, A. S. Inhibition of Angiogenesis by Nonsteroidal Anti-Inflammatory Drugs: Insight Into Mechanisms and Implications for Cancer Growth and Ulcer Healing. Nat. Med. 1999, 5, 1418-1423.
88. Sawaoka, H.; Tsuji, S.; Tsujii, M.; Gunawan, E. S.; Sasaki, Y.; Kawano, S.; Hori, M. Cyclooxygenase Inhibitors Suppress Angiogenesis and Reduce Tumor Growth in vivo. Lab. Invest. 1999, 79, 1469-1477.
89. Liu, X. H.; Kirschenbaum, A.; Yao, S.; Lee, R.; Holland, J. F.; Levine, A. C. Inhibition of Cyclooxygenase-2 Suppresses Angiogenesis and the Growth of Prostate Cancer in vivo. J. Urol. 2000, 164, 820-825.
90. Amano, H.; Hayashi, I.; Endo, H.; Kitasato, H.; Yamashina, S.; Maruyama, T.; Kobayashi, M.; Satoh, K.; Narita, M.; Sugimoto, Y.; Murata, T.; Yoshimura, H.; Narumiya, S.; Majima, M. Host Prostaglandin E(2)-EP3 Signaling Regulates Tumor-Associated Angiogenesis and Tumor Growth. J. Exp. Med. 2003, 197, 221-32.
91. Fujita, H.; Koshida, K.; Keller, E. T.; Takahashi, Y.; Yoshimito, T.; Namiki, M.; Mizokami, A. Cyclooxygenase-2 Promotes Prostate Cancer Progression. Prostate 2002, 53, 232-240.
92. Mohammed, S. I.; Bennett, P. F.; Craig, B. A.; Glickman, N. W.; Mutsaers, A. J.; Snyder, P. W.; Widmer, W. R.; Degortari, A. E.; Bonney, P. L.; Knapp, D. W. Effects of the Cyclooxygenase Inhibitor, Piroxicam, on Tumor Response, Apoptosis, and Angiogenesis in A Canine Model of Human Invasive Urinary Bladder Cancer. Cancer Res. 2002, 62, 356-358.
93. Rozic, J. G.; Chakraborty, C.; Lala, P. K. Cyclooxygenase Inhibitors Retard Murine Mammary Tumor Progression by Reducing Tumor Cell Migration, Invasiveness and Angiogenesis. Int. J. Cancer 2001, 93, 497-506.
94. Piazza, G. A.; Alberts, D. S.; Hixson, L. J.; Paranka, N. S.; Li, H.; Finn, T.; Bogert, C.; Guillen, J. M.; Brendel, K.; Gross, P. H.; Sperl, G.; Ritchie, J.; Burt, R. W.; Ellsworth, L.; Ahnen, D. J.; Pamukcu, R. Sulindac Sulfone Inhibits Azoxymethane-Induced Colon Carcinogenesis in Rats Without Reducing Prostaglandin Levels. Cancer Res. 1997, 57, 2909-2915.
95. Stoner, G. D.; Budd, G. T.; Ganapathi, R.; Deyoung, B.; Kresty, L. A.; Nitert, M.; Fryer, B.; Church, J. M.; Provencher, K.; Pamukcu, R.; Piazza, G.; Hawk, E.; Kelloff, G.; Elson, P.; Van Stolk, R. U. Sulindac Sulfone Induced Regression of Rectal Polyps in Patients with Familial Adenomatous Polyposis. Adv. Exp. Med. Biol. 1999, 470, 45-53.
96. Piazza, G. A.; Rahm, A. L. K.; Krutzsch, M.; Sperl, G.; Paranka, N. S.; Gross, P. H.; Brendel, K.; Burt, R. W.; Alberts, D. S.; Pamukcu, R.; Ahnen, D. J. Antineoplastic Drugs Sulindac Sulfide and Sulfone Inhibit Cell Growth by Inducing Apoptosis. Cancer Res. 1995, 55, 3110-3116.
97. Liu, L.; Li, H.; Underwood, T.; Lloyd, M.; David, M.; Sperl, G.; Pamukcu, R.; Thompson, W. J. Cyclic GMP-Dependent Protein Kinase Activation and Induction by Exisulind and CP461 in Colon Tumor Cells. J. Pharmacol. Exp. Ther. 2001, 299, 583-592.
98. Hanif, R.; Pittas, A.; Feng, Y.; Koutsos, M. I.; Qiao, L.; Staiano-Coico, L.; Shiff, S. I.; Rigas, B. Effects of Nonsteroidal Anti-Inflammatory Drugs on Proliferation and on Induction of Apoptosis in Colon Cancer Cells by A Prostaglandin-Independent Pathway. Biochem. Pharmacol. 1996, 52, 237-245.
99. Zhang, X.; Morham, S. G.; Langenbach, R.; Young, D. A. Malignant Transformation and Antineoplastic Actions of Nonsteroidal Antiinflammatory Drugs (Nsaids) on Cyclooxygenase-Null Embryo Fibroblasts. J. Exp. Med. 1999, 190, 451-459.
100. Yamamoto, Y.; Yin, M. J.; Lin, K. M.; Gaynor, R. B. Sulindac Inhibits Activation of the NF-KappaB Pathway. J. Biol. Chem. 1999, 274, 27307-27314.
101. Grilli, M.; Pizzi, M.; Memo, M.; Spano, P. Neuroprotection by Aspirin and Sodium Salicylate through Blockade of NF-κB Activation. Science 1996, 274, 1383-1385.
102. Yin, M. J.; Yamamoto, Y.; Gaynor, R. B. the Anti-Inflammatory Agents Aspirin and Salicylate Inhibit the Activity of I(Kappa)B Kinase-Beta. Nature 1998, 396, 77-80.
103. Poligone, B.; Baldwin, A. S. Positive and Negative Regulation of NF-Kappab by COX-2: Roles of Different Prostaglandins. J. Biol. Chem. 2001, 276, 38658-38664.
104. Hsu, A. L.; Ching, T. T.; Wang, D. S.; Song, X.; Rangnekar, V. M.; Chen, C. S. the Cycloexygenase-2 Inhibitor Celecoxib Induces Apoptosis by Blocking Akt Activation in Human Prostate Cancer Cells Independently of Bcl-2. J. Biol. Chem. 2000, 275, 11397-11403.
105. Gupta, R. A.; Tan, J.; Krause, W. F.; Geraci, M. W.; Willson, T. M.; Dey, S. K.; Dubois, R. N. Prostacyclin-Mediated Activation of Peroxisome Proliferator-Activated Receptor Delta in Colorectal Cancer. Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13275-13280.
106. He, T. C.; Chan, T. A.; Vogelstein, B.; Kinzler, K. W. Ppardelta Is An APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs. Cell 1999, 99, 335-345.
107. Wick, M.; Hurteau, G.; Dessev, C.; Chan, D.; Geraci, M. W.; Winn, R. A.; Heasley, L. E.; Nemenoff, R. A. Peroxisome Proliferator-Activated Receptor-Gamma Is A Target of Nonsteroidal Anti-Inflammatory Drugs Mediating Cyclooxygenase-Independent Inhibition of Lung Cancer Cell Growth. Mol. Pharmacol. 2002, 62, 1207-1214.
108. Girnun, G. D.; Smith, W. M.; Drori, S.; Sarraf, P.; Mueller, E.; Eng, C. ; Nambiar, P.; Rosenberg, D. W.; Bronson, R. T.; Edelmann, W.; Kucherlapati, R. ; Gonzalez, F. J.; Spiegelman, B. M. APC-Dependent Suppression of Colon Carcinogenesis by Ppargamma. Proc. Natl. Acad Sci. U.S.A. 2002, 99, 13771-13776.
109. Park, B. H.; Vogelstein, B.; Kinzler, K. W. Genetic Disruption of Ppardelta Decreases the Tumorigenicity of Human Colon Cancer Cells. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 2598-2603.
110. Giardiello, F. M. NSAID-Induced Polyp Regression in Familial Adenomatous Polyposis Patients. Gastroenterol. Clin. North Am. 1996, 25, 349-362.
111. Lin, E. H. Celecoxib Attenuated Capecitabine Induced Hand-And-Foot Syndrome (HFS) and Diarrhea Andimproved Time to Tumor Progression in Metastatic Colorectal Cancer (MCRC). Proc. Am. Soc. Clin. Oncol. 2002, 21, 2364.
112. Blanke, C. D. A Phase II Trial of Celecoxib, Irinotecan, 5-Florouracil, and Leucovorin in Patients with Unresectable or Metastatic Colorectal Cancer. Proc. Am. Soc. Clin. Oncol. 2002, 21, 505.